Core Insights - The field of robotic surgery is rapidly emerging, with Intuitive Surgical (NASDAQ: ISRG) being a leading player due to its established market presence and growing installed base of surgical robots [1][7] Demand and Growth - As of Q3 2025, Intuitive Surgical had installed 10,763 da Vinci surgical robot systems, marking a 13% increase from 9,539 in Q3 2024, indicating strong demand for its medical devices [3] - The number of surgeries performed using da Vinci systems increased by 20% year over year, surpassing the growth in the number of robots, which suggests a growing acceptance and preference for robotic-assisted surgeries [4] - The technology enables less invasive procedures and improved surgical outcomes, leading to increased interest from both doctors and patients [5] Regulatory Approvals and Market Potential - Intuitive Surgical received FDA approval for da Vinci systems to perform additional procedures, including inguinal hernia repairs, cholecystectomies, and appendectomies, which expands the potential applications of its technology [5] Investment Considerations - The current price-to-earnings (P/E) ratio for Intuitive Surgical is around 75, which is high but aligns with its five-year average, indicating that the stock may be fully priced [6] - For growth investors, Intuitive Surgical presents an attractive opportunity, with revenue increasing nearly 90% and earnings rising over 150% in the past five years, alongside a stock price gain of just over 100% [8]

Core Insights - SS Innovations International, Inc. has developed five new 5-millimeter surgical instruments aimed at enhancing robotic surgery across various specialties, including pediatric, cardiac, and head and neck surgery [1][2][3] Company Developments - The new instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps, designed for use in critical surgical procedures [2] - The cumulative installed base of the SSi Mantra surgical robotic system reached 168 systems as of December 31, 2025, with 12 systems deployed in nine countries outside of India [3] - Over 7,800 surgical procedures have been performed using the SSi Mantra, including more than 120 telesurgeries and over 400 cardiac procedures [3] Market Opportunity - Approximately 1.7 billion children and adolescents globally lack access to essential surgical care, with over 390 million children under five in lower- and middle-income countries not receiving timely surgical interventions [3] - The development of smaller surgical instruments aims to make robotic surgery more accessible to pediatric patients, addressing a significant gap in the current healthcare landscape [3] Product Features - The SSi Mantra surgical robotic system is characterized by its user-friendly, modular design, featuring 3 to 5 robotic arms, a 3D 4K monitor, and advanced imaging capabilities [6] - The system has been clinically validated in India for over 100 different types of surgical procedures, showcasing its versatility and effectiveness [6] Future Focus - The company plans to continue developing differentiated surgical robotic technologies to benefit a larger segment of patients globally, particularly in underserved populations [3]

Core Insights - CONMED Corporation (CNMD) is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs) [1][4][10] - The company is facing challenges from tariffs impacting gross margins and the launch of Intuitive Surgical's da Vinci 5, which delays AirSeal demand [2][15] Company Performance - CONMED has a market capitalization of $1.28 billion and projects a 3.4% earnings growth over the next five years, with earnings surpassing estimates in the last four quarters, averaging an 8.40% surprise [3][17] - The company reported significant progress in stabilizing its orthopedic supply chain, achieving record manufacturing volumes and reducing critical SKU shortages [11][12] Growth Drivers - Adoption of BioBrace has expanded to over 70 procedures, indicating strong surgeon uptake and versatility in soft-tissue repair applications [4] - AirSeal utilization is increasing due to its clinical benefits, while Buffalo Filter growth is supported by expanding smoke-evacuation mandates [5][10] - The expansion of robotic surgery and ASC penetration presents a meaningful growth opportunity, with incremental AirSeal utilization driven by the redeployment of Intuitive Surgical's Xi systems [6][9] Challenges - Tariffs are reducing gross margins by approximately 20 basis points in Q3, with expectations of a 150 basis point impact in Q4 [13] - The supply-chain recovery is ongoing and is expected to take one to two quarters for normalization, which may temper revenue recovery [14] - The integration of the da Vinci 5 is constraining near-term AirSeal adoption, as hospitals may not need to purchase AirSeal immediately due to the integrated insufflation system [15][16]

Core Insights - Intuitive Surgical's single-port (SP) platform is emerging as a significant growth driver, with SP procedures increasing by 91% year-over-year in Q3 2025, surpassing overall da Vinci growth and indicating strong adoption, especially outside the U.S. [1][12] Adoption and Utilization - The highest adoption rates are observed in Korea, where SP utilization has surpassed that of the legacy Xi system, indicating a shift from novelty to routine clinical use [2][12] - In the U.S., SP adoption is in its early stages, but the market is expanding with initial domestic use of the SP stapler in colorectal and thoracic procedures, which are substantial procedural categories [4][12] Clinical Evidence and Regulatory Developments - Management highlighted growing clinical evidence that SP offers patient benefits beyond cosmetic outcomes, potentially improving recovery times and length of hospital stays, which could influence adoption among surgeons and hospital administrators [3] - Regulatory momentum is crucial, with completed U.S. regulatory submissions for nipple-sparing mastectomy and other general surgery indications, aiming to replicate Korea's adoption curve in the U.S. market [5] Strategic Considerations - The key question for investors is whether SP will serve as an incremental growth driver or primarily replace multiport da Vinci volumes. Management suggests that SP's unique features may enable minimally invasive surgery in patient populations not well served by multiport systems [6] - Although SP currently contributes modestly in absolute terms, its growth trajectory indicates a potential transition from niche to mainstream, contingent on continued regulatory expansion and clinical evidence [7] Peer Updates - Stryker's robotic surgery segment showed strong momentum, achieving record Mako installations and expanding usage across various surgical cases, supported by software enhancements [8] - Globus Medical's robotics and navigation ecosystem is scaling, with the launch of ExcelsiusXR, a wearable navigation headset aimed at improving surgeon focus and ergonomics [10]

Core Insights - Intuitive Surgical's (ISRG) third-quarter results show a 20% year-over-year increase in combined da Vinci and Ion procedures, raising questions about the sustainability of this growth rate [2][6] Company Performance - da Vinci procedures grew by 19%, while Ion volumes surged by 52%, with growth observed across various surgical fields including general surgery, gynecology, and international markets [3] - The introduction of da Vinci 5 has led to higher utilization rates compared to previous Xi systems, with U.S. utilization turning positive after being flat earlier in the year [3] - Management noted that some elective procedures may have been advanced due to uncertainties around Medicare funding, although this has not been confirmed by third-party data [4] - Bariatric procedures are declining at high single-digit rates due to the adoption of GLP-1 therapies, highlighting that not all surgical demand is immune to therapeutic changes [5] Market Dynamics - International growth was slightly aided by holiday timing shifts, contributing approximately one percentage point to growth [4] - Hospital budget constraints, particularly outside the U.S., and macro health policy changes could impact future capital and utilization momentum [5] Valuation and Estimates - ISRG's shares have increased by 8.1% over the past six months, compared to a 14.8% rise in the industry [12] - The company trades at a forward price-to-earnings ratio of 60.4, which is above the industry average but below its five-year median of 71.52 [13] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 17.9% increase from the previous year [15]

Core Insights - Sands Capital Global Growth Fund reported a -2.0% return in Q3 2025, underperforming the MSCI ACWI which returned 7.6% [1] - The fund focuses on identifying promising growth companies globally, with a notable emphasis on stocks like Intuitive Surgical, Inc. [2] Company Overview: Intuitive Surgical, Inc. - Intuitive Surgical, Inc. is a leading provider of soft-tissue robotic surgical systems, with a market capitalization of $198.804 billion as of December 16, 2025 [2][3] - The company's stock experienced a one-month return of 3.49% and a 52-week gain of 3.23% [2] Performance Analysis - Despite a decline in stock price during Q3 2025 due to concerns over U.S. hospital budgets, Intuitive Surgical exceeded consensus expectations across all metrics, showcasing strong operating margins [3] - Da Vinci 5 placements increased by 22% quarter-over-quarter, indicating robust demand even before new product launches in the EU and Japan [3] Market Position and Future Outlook - The health care sector, particularly medical equipment, underperformed in Q3 2025, but Intuitive Surgical's fundamentals remained strong [3] - Management's stock repurchase of $180 million reflects confidence in the company's future, as it enters a new robot upgrade cycle [3] - Enthusiasm for robotic cardiothoracic procedures could potentially expand Intuitive's U.S. addressable market by 5 to 10% [3] Hedge Fund Interest - Intuitive Surgical was held by 99 hedge fund portfolios at the end of Q3 2025, a decrease from 107 in the previous quarter, indicating a shift in investor interest [4]

Core Viewpoint - SS Innovations has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, targeting multiple surgical specialties and aiming for U.S. market entry [1][3][5] Company Overview - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [8] - The company is headquartered in India and plans to expand its global presence with cost-effective surgical robotic solutions [8] Product Details - The SSi Mantra surgical robotic system supports various surgical specialties, including general, urological, colorectal, gynecological, and cardiac procedures [2][3] - The system features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, a large 3D 4K monitor, and over 40 types of robotic endo-surgical instruments [10] Regulatory Progress - The 510(k) submission is part of the company's strategic plan to introduce the SSi Mantra system to the U.S. market, with the expectation of a review completion within 90 days, although actual approval may take longer [6] - The company is also pursuing EU CE Mark approval, which it anticipates could be obtained in the first half of 2026 [6] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system and over 7,300 surgical procedures performed [6]

Core Insights - CONMED Corporation (CNMD) is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs) [1][4][5] - The company faces challenges from tariff impacts on gross margins and the launch of Intuitive Surgical's da Vinci 5, which delays AirSeal demand [2][11][13] - CONMED has a market capitalization of $1.38 billion and projects a 6.3% earnings growth for 2026, with a history of surpassing earnings estimates [3] Growth Drivers - The adoption of high-margin platforms is strong, with BioBrace expanding to over 70 procedures, AirSeal gaining traction for its clinical benefits, and Buffalo Filter benefiting from smoke-evacuation mandates [4][7] - The expansion of robotic surgery and ASC penetration is expected to provide structural long-term growth opportunities [5][8] - Supply chain improvements are unlocking lost revenue and margin, with significant progress reported in orthopedic supply chain recovery [9] Strategic Focus - A comprehensive portfolio review is ongoing, focusing on high-return segments such as minimally invasive surgery, robotic platforms, and orthopedic soft-tissue repair [10] - Management aims to concentrate resources on these areas to improve margins and enhance shareholder value [10] Challenges - Tariffs are compressing gross margins, with an expected impact of 150 basis points in the fourth quarter [11] - The supply chain recovery is taking longer than anticipated, which may delay revenue recovery and affect market share [12] - The integration of the dV5 system limits the immediate opportunity for AirSeal adoption [13] Financial Outlook - There is a rising estimate revision trend for 2025, with the Zacks Consensus Estimate for earnings moving up to $4.49 per share [14]

Uh, you see this photograph? I think there is nobody in this hall who must not have had a relative or somebody he knows who has not suffered from obesity. The problem of being overweight either some of your relatives would have suffered it or you yourself would have. And the problem with obesity is that there is just not the weight of the body there is also that weight of the shame. But guess this is the surprise. I never wanted to treat obesity in my life. Never. In fact, all I wanted to be is to become th ...

Core Insights - Intuitive Surgical is a leader in robotic surgery equipment with over 9,900 da Vinci systems installed globally, used in more than 16 million procedures [1] - Approximately 25% of Intuitive Surgical's revenue comes from system sales, while the remaining 75% is generated from servicing and supplies, providing a stable revenue stream [2] - The company's stock is highly valued, with a forward P/E ratio of 59, slightly above its five-year average of 56, reflecting its status as a strong growth stock [3] Company Comparisons - Medtronic is making strides in robotic surgery and offers a more attractive valuation with a forward P/E of 18, just above its five-year average of 17 [4] - Medtronic has focused on higher-margin operations and divested its less profitable diabetes division, maintaining a solid dividend yield of 2.8% [5] - Medtronic's recent earnings report indicated robust procedure volumes and market performance, with revenue and EPS exceeding expectations [5]